恒瑞医药：子公司注射用瑞康曲妥珠单抗上市申请获受理，并被纳入优先审评

财中社07-02

　　7月2日，恒瑞医药（600276/01276）发布公告，子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。

　　公司注射用瑞康曲妥珠单抗已在国内获批两项适应症，分别为：用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者；用于治疗既往接受过一种或一种以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。

　　截至目前，注射用瑞康曲妥珠单抗相关项目累计研发投入约20.77亿元。

　　2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2648032985?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-02 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648032985","market":"us","top_or_hot":-1,"title":"恒瑞医药：子公司注射用瑞康曲妥珠单抗上市申请获受理，并被纳入优先审评","media":"财中社","content":"<html><body><div>\n<p>　　7月2日，<span><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></span>（600276/01276）发布公告，子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。</p><p>　　公司注射用瑞康曲妥珠单抗已在国内获批两项适应症，分别为：用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者；用于治疗既往接受过一种或一种以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。</p><p>　　截至目前，注射用瑞康曲妥珠单抗相关项目累计研发投入约20.77亿元。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.01276\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/01276\">恒瑞医药</a></span>实现收入81.41亿元，归母净利润22.82亿元。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药：子公司注射用瑞康曲妥珠单抗上市申请获受理，并被纳入优先审评</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药：子公司注射用瑞康曲妥珠单抗上市申请获受理，并被纳入优先审评\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　7月2日，<span><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></span>（600276/01276）发布公告，子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。</p><p>　　公司注射用瑞康曲妥珠单抗已在国内获批两项适应症，分别为：用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者；用于治疗既往接受过一种或一种以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。</p><p>　　截至目前，注射用瑞康曲妥珠单抗相关项目累计研发投入约20.77亿元。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.01276\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/01276\">恒瑞医药</a></span>实现收入81.41亿元，归母净利润22.82亿元。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202607023791965633.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1328615791.USD","symbol_name":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607023791965633.html","article_id":"2648032985","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648032985","pubTimestamp":1782982860,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"7月2日，恒瑞医药（600276/01276）发布公告，子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","01276":"恒瑞医药","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0239":"医药制造","LU1997245177.USD":"安联神洲A股基金","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK0183":"MSCI概念","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0188":"融资融券","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0012":"证金概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0028":"国家队","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1191":"制药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0196":"行业龙头","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","IPOS":"Renaissance International IPO ETF","LU0359201612.USD":"贝莱德中国基金A2"},"translate_title":"Hengrui Medicine: The marketing application of the subsidiary's Ruikangtrastuzumab for injection was accepted and included in the priority review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5,"IPOS":1.5},"content_text":"7月2日，恒瑞医药（600276/01276）发布公告，子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。　　公司注射用瑞康曲妥珠单抗已在国内获批两项适应症，分别为：用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者；用于治疗既往接受过一种或一种以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。　　截至目前，注射用瑞康曲妥珠单抗相关项目累计研发投入约20.77亿元。　　2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648032985","isCrawlerRequest":true}